Thiazolidinedione Derivative Suppresses LPS-induced COX-2 Expression and NO Production in RAW 264.7 Macrophages

authors:

avatar Mehrnaz Rezaei a , avatar Hossein Ghafouri b , * , avatar Mahmood Reza Aghamaali b , avatar Mostafa Shourian b

Department of Biology, Faculty of Science, University of Guilan, University Campus 2, Rasht, Iran.
Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran.
Iranian Journal of Pharmaceutical Research : IJPR: Vol.18, issue 3; 1371-1379
article type: Original Article
received: August , 2017
accepted: November , 2017
DOI: https://doi.org/10.22037/ijpr.2019.1100730

how to cite: Rezaei M, Ghafouri H, Aghamaali M R, Shourian M. Thiazolidinedione Derivative Suppresses LPS-induced COX-2 Expression and NO Production in RAW 264.7 Macrophages. Iran J Pharm Res. 2019;18(3):e126185. https://doi.org/10.22037/ijpr.2019.1100730.

Abstract

The present study was designed to investigate the inhibitory effect of 2,4 bis-[(4-ethoxyphenyl)azo] 5-(3-hydroxybenzylidene) thiazolidine-2,4-dione (TZD-OCH2CH3) on the cyclo-oxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in RAW 264.7 cells. The effects of TZD-OCH2CH3 on COX-2 and iNOS mRNA expression in LPS-activated RAW 264.7 cells were detected by real time PCR. Also, to understand structure and substrate specificity, we have utilized molecular docking simulations (AutoDock Vina) and the active residues in the binding pocket were determined from COX-2 and iNOS. The treatment of RAW 264.7 cells with TZD-OCH2CH3 significantly inhibited LPS-induced COX-2 mRNA expression, corresponding to 46.1% and 61.06% at 30 and 60 μg/mL, respectively. The present study revealed that the TZD-OCH2CH3 had a little effect on iNOS mRNA expression. Meanwhile, the TZD-OCH2CH3 also could inhibit the production of NO compared to single LPS-stimulated cell. According to the results obtained, TZD-OCH2CH3 dramatically suppressed lipopolysaccharide (LPS) induced nitric oxide (NO) production after 24 h, in a concentration-dependent manner with an IC50 of 65 μg/mL. Our data suggest that TZD-OCH2CH3, as a functionally novel agent, inhibits the inflammatory pathway via suppression of COX-2 mRNA expression and also by the inhibition of the iNOS activity. Therefore, this compound could be suggested as a novel therapeutic strategy for inflammation-associated disorders.

Introduction

Prostaglandin H2 synthase (PGH2) or COX-2, is chiefly responsible for catalyzing the key step in prostaglandins synthesis as an important biological mediator, that triggers all most inflammation features (1-3). The non-selective inhibitors non-steroidal anti-inflammatory drugs (NSAIDs) are used worldwide for control of inflammation and pain (4, 5). A number of epidemiological studies have concluded that the use of aspirin and other NSAIDs may protect us against the formation of gastrointestinal tumors by inhibitory effects on COXs (6-8). Recent studies suggest that this anticancer effect may be the result of inhibition of COX-2 (7). Several families of compounds having selective COX-2 inhibitory potential have been introduced such as celecoxib, etoricoxib, and rofecoxib (9, 10). However, because of some potential adverse effect such as gastric ulcer, gastrointestinal bleeding, and cardiovascular problems associated with NSAIDs, they have been voluntarily withdrawn from the market (11, 12). It is well-known that a number of heterocyclic compounds exhibit a wide range of pharmacological features (13-15). Substituted thiazolidine-2,4-dionesare is one of the most important heterocyclic compounds with multiple applications (16, 17). There are various pharmaceutical compounds containing the thiazolidine capable of undergoing tautomerism that usually involve migration of mobile proton from one site to another within the molecule (16, 18). Due to this feature, thiazolidine and its derivatives as bioactive heterocycles used as scaffolds for novel drug discovery (19). On the other hand, the thaizolidinediones group, as a known basic pharmacophore for various biological profiles such as antibacterial, anti-HIV, antitumor, and antidiabetic (20-22). «Over the past decades a number of thiazolidine were intensively studied for their anti-hyperglycaemic property (23, 24). Besides, it is reported that 3-thiazolidine-4-one derivatives afforded a new scaffold for anti-inflammatory feature (25, 26). Also, (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione reported as effective pharmacophore for pro-inflammatory cytokines inhibition (27). In addition, one recent study has shown that a series of thiazolidin-4-one derivatives as novel inhibitors of COX-2 (28). The recent success of thiazolidineas inflammatory mediator’s inhibitor has grown considerable attention towards thiazolidine nucleus in the designing of newer anti-inflammatory drugs. Therefore, we investigated the effects of TZD-OCH2CH3 on changes of COX-2 and iNOS expression in RAW 264.7 macrophage cells, which can be stimulated with LPS to mimic the condition of infection and inflammation.

Experimental

Murine monocytic macrophage cell line RAW264.7 cells were purchased from Iranian Biological Resource Center (IBRC). Lipopolysaccharide (Escherichia coli 0127: E8) was purchased from Sigma Chemical Co. Dulbecco’s modified essential medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco BRL (Grand Island, NY, USA). Total RNA extraction (RNeasy mini kit) and cDNA synthesis kit was obtained from Qiagen. SYBR® Green Real-Time PCR Master was purchased from Thermo Fisher Scientific. MTT and all other chemicals were provided by Merck (Germany). T75, T25 flasks, and 96-well plates were distributed by SPL life science (Korea).

Chemical synthesis

2,4 bis-[(4-ethoxyphenyl)azo]5-(3-hydroxybenzylidene) thiazolidine-2,4-dione (TZD-OCH2CH3) was synthesized by treating the corresponding aryl diazonium salts with 5-(3-hydroxybenzylidene) thiazolidine-2,4-dione in alkaline media using diazotization-coupling reactions, as previously described (29). The structure of TZD-OCH2CH3 was confirmed by 1H NMR and FT-IR spectroscopy. IR spectra were recorded on a Shimadzu 8400 FT-IR spectrophotometer. The 1H NMR spectra were obtained on a FT-NMR (400 MHz) Brucker apparatus spectrometer.

Cell culture

The cells were maintained in complete DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 μg/mL of streptomycin and 1.5% sodium bicarbonate at 37 °C and 5% CO2. They were then transferred to medium containing 10% DMSO, frozen in liquid nitrogen for long-term storage. The cells were plated at a density of 1 × 105 cells/T-25 flask plate for 48 h.

Cell proliferation assay

The murine macrophage cell line RAW 264.7 proliferation was evaluated using the MTT assay as described by Scudiero et al. (30). For stimulation, the medium was replaced with 0.1% FBS contained DMEM, and the cells were then stimulated with 1 μg/mL of LPS and were treated with various concentrations of TZD-OCH2CH3 for 24 and 48 h. Some cells were grown in 1% DMSO as a negative control. At the end of treatment period, 50 μL of MTT solution (0.5 mg/mL) was added to each well and the plate was incubated for 3 h. The supernatant were removed and formazan crystals formed were solubilized in 50 μL of DMSO for 30 min. The absorbance at 570 nm was measured using a Multi-Mode Microplate reader (BioTek Winooski, VT, USA). The results were expressed as percentage of the control (considered as 100%).

Nitrite measurement

Accumulated nitrite concentration in the cells culture media was measured following Granger et al assay with some modifications (31). RAW 264.7 macrophages were seeded at a density of 5 × 103 cells/well and incubated overnight. Then, cells were treated with TZD-OCH2CH3 at concentrations ranging from 0-60 μg/mL for 24 h at the presence or absence of 1 μg/mL LPS. 100 μL of cells supernatants were collected and treated with 100 μL of Griess reagent and after 10 min incubation at room temperature the absorbance at 570 nm was measured using Multi-Mode Microplate reader. Sodium nitrite (0–100 µM) was used as standard for the generation a calibration curve.

RNA extraction and Real time PCR

The mRNA levels of LPS-induce COX-2 and iNOS were determined in RAW246.7 macrophage cells. Total RNA was extracted from RAW246.7 macrophage cells using Qiagen kit according to the manufacturer’s instruction. RAW246.7 macrophage cells were treated with TZD-OCH2CH3 at concentrations ranging from 20 to 100 μM for 18 h at the presence or absence of 1 μg/mL LPS. cDNA was amplified using real-time PCR (Applied Biosystems™) with the Fast Start DNA Master SYBR Green I kit. The copy number of each transcript was calculated as the relative copy number normalized by GAPDH copy number. Total RNA was converted to cDNA using a Reverse Transcription System (Qiagen). The target cDNA was amplified using the primers listed in Table 1. Briefly, each amplification reaction contained 25 ng of the cDNA, 0.5 μL (10 pmol/μL) of each primer and 6 μL CYBR green real time-PCR master mix. PCR was performed using the following amplification program: Initial denaturation for 3 min at 94 °C, followed by 35 cycles at 94 °C for 10 sec, 56 °C for 30 sec and 72 °C for 30 sec for COX-2 and 35 cycles at 94 °C for10 sec, 56 °C for 30 sec and 72 °C for 30 sec for iNOS. Melting curve was recorded by cooling the PCR product to 60 °C for 30 sec and then slowly heating it to 94 °C at 0.1 °C/sec to ensure absence of nonspecific products.

Docking

The feasibility of TZD-OCH2CH3 to be ligand for COX-2 and iNOS structures was evaluated using molecular docking. Protein structures were obtained from the RCSB Protein Data Bank (3LN1 and 4UX6 respectively). Missing hydrogen atoms were added to the crystal structures by REDUCE program (32) that also reproduces the correct protonation states of histidine residues and optimizes some sort of side chain flexibilities via a sequence of flipping and rotating movements. All docking simulations were performed by AutoDock Vina program (33), while MGLTools (34) was used for the preparation of necessary input files. A standard docking protocol was adopted that includes addition of Gasteiger atomic charges and assignment of default atom-types. In the accurate docking step, the exhaustiveness parameter was set to 1000.

Ligand structure was model built and optimized by HyperChem program version 7 using amber force filed (35). Images were created using Python Molecule Viewer (PMV) and the program LigPlot‏ v.1.0, which generates schematic 2-D representations of protein-ligand complexes from the PDB file input (36).

Statistical analysis

All experiments were done in triplicates and the results were expressed as the mean ± SD. Comparison between groups was made with One-way ANOVA analysis with post hoc Newman–Keuls tests. P-values less than 0.05 were considered statistically significant.

Results

Effects of TZD-OCH2CH3 on RAW 264.7 cells proliferation

We first measured the cytotoxic effect of TZD-OCH2CH3 on RAW 264.7 cells. The result showed that dimethyl sulfoxide (DMSO) as the solvent of TZD-OCH2CH3 had no effect on the proliferation of RAW 264.7 cells at concentrations up to 1.5% (not shown results). In following, the viability of the cells stimulated by LPS (1 µg/mL) for 24 h in the presence of TZD-OCH2CH3 (0-300 µg/mL) was investigated. As shown in Figure 1, the viability of the cells treated for 24 h were not significantly affected by TZD-OCH2CH3 up to 60 μg/mL compared to the control. Therefore, TZD-OCH2CH3 concentrations of 30, and 60 μg/mL were used in the subsequent experiments.

Inhibition of nitrite production by TZD-OCH2CH3

To investigate the anti-inflammatory effects of TZD-OCH2CH3, we tested its effect on NO production in LPS-activated RAW 264.7 cells.

As shown in Figure 2, TZD-OCH2CH3 inhibited nitrite production about 45% at 60 μg/mL. As shown in Figure 2, TZD-OCH2CH3 was inhibitory effects on the production of NO in LPS-induced RAW 264.7 cells with an IC50 of 65 μg/mL in a concentration-dependent manner. LPS treatment of the RAW 264.7 cells increased NO production about 70% over the basal level.

However, it decreased by 76.4% and 56.2% in the presence of 30 and 60 μg/mL of TZD-OCH2CH3, respectively, compared with the LPS alone (100%).

Inhibition of COX-2 and iNOS mRNA expression by TZD-OCH2CH3

The effect of TZD-OCH2CH3 on the expression of COX-2 and iNOS mRNA in LPS-activated RAW 264.7 cells was shown in Figure 3. No any expression of COX-2 and iNOS mRNA was found in unstimulated macrophages while LPS-activated RAW 264.7 cells dramatically induced the COX-2 and iNOS mRNA expression. LPS treatment of the RAW 264.7 cells increased the COX-2 and iNOS mRNA expression about 33.34 and 11.24-fold over the basal level, respectively. The inhibitory effect of TZD-OCH2CH3 on COX-2 and iNOS mRNA expression at 0-60 μg/mL was in a concentration-dependent manner, indicating that TZD-OCH2CH3 showed considerable inhibitory effect on the expression of iNOS and COX-2 mRNA in LPS-activated macrophages compared to the control cells. The treatment of LPS-activated RAW 264.7 cells with TZD-OCH2CH3 significantly inhibited LPS-induced COX-2 mRNA expression, corresponding to 46.1% and 61.06% in the presence of 30 and 60 μg/mL, respectively.

Table 1

Sequences of forward and reverse primers

Primer SequenceTm (°C)
COX-2 F ATATCAGGTCATCGGTGGAGAG 64.9
COX-2 R CACTCTGTTGTGCTCCCGAA 65.4
iNOS F GTGCTAATGCGGAAGGTCAT 64.3
iNOS R AAATGTGCTTGTCACCACCAG 64.7
Effect of TZD-OCH2CH3 on cell viability in LPS-stimulated RAW264.7 cells. (A) Before and 24 h after TZD-OCH2CH3 treatment. (B) Cells were incubated in the presence of TZD-OCH2CH3 (0-300 μg/mL) with the addition of 1 µg/mL LPS for 24 h. Cell viability was determined by the MTT assay. Values represent the means ± SDs of three independent experiments. *P < 0.05 indicates statistically significant differences from the control group

Effect of TZD-OCH2CH3 on cell viability in LPS-stimulated RAW264.7 cells. (A) Before and 24 h after TZD-OCH2CH3 treatment. (B) Cells were incubated in the presence of TZD-OCH2CH3 (0-300 μg/mL) with the addition of 1 µg/mL LPS for 24 h. Cell viability was determined by the MTT assay. Values represent the means ± SDs of three independent experiments. *P < 0.05 indicates statistically significant differences from the control group

Figure 1

Effect of TZD-OCH2CH3 on LPS-induced NO level in RAW 264.7 cells. The cells were stimulated with 1 μg/mL of LPS only or with different concentrations of TZD-OCH2CH3 for 24 h. NO levels were determined using Griess assays in culture media. Values represent the means ± SDs of three independent experiments. *P < 0.05 indicates statistically significant differences from the control group

Effect of TZD-OCH2CH3 on LPS-induced NO level in RAW 264.7 cells. The cells were stimulated with 1 μg/mL of LPS only or with different concentrations of TZD-OCH2CH3 for 24 h. NO levels were determined using Griess assays in culture media. Values represent the means ± SDs of three independent experiments. *P < 0.05 indicates statistically significant differences from the control group

Figure 2

Effect of TZD-OCH2CH3 on the mRNA expression of COX-2 and iNOS in LPS-activated RAW 264.7 cells. RAW 264.7 cells were pretreated with various concentration of TZD-OCH2CH3 (15, 30 and 60 μg/mL) for 1 h before being incubated with LPS (1 μg/mL) for 18 h. Total RNAs were isolated and mRNA expression of COX-2 and iNOS was determined by real-time RT–PCR. Data represent three independent experiments and are expressed as mean ± SDs. *P < 0.05 indicates statistically significant differences from the control group

Effect of TZD-OCH2CH3 on the mRNA expression of COX-2 and iNOS in LPS-activated RAW 264.7 cells. RAW 264.7 cells were pretreated with various concentration of TZD-OCH2CH3 (15, 30 and 60 μg/mL) for 1 h before being incubated with LPS (1 μg/mL) for 18 h. Total RNAs were isolated and mRNA expression of COX-2 and iNOS was determined by real-time RT–PCR. Data represent three independent experiments and are expressed as mean ± SDs. *P < 0.05 indicates statistically significant differences from the control group

Figure 3

3D secondary structure of COX-2 (A) and iNOS (B) binding site that shows the three dimensional position of TZD-OCH2CH3 at the binding site of the protein

3D secondary structure of COX-2 (A) and iNOS (B) binding site that shows the three dimensional position of TZD-OCH2CH3 at the binding site of the protein

Figure 4

Two dimensional plot of COX-2 (A) and iNOS (B) at the present of TZD-OCH2CH3. LigPlot v.1.0, which generates from the PDB file input

Two dimensional plot of COX-2 (A) and iNOS (B) at the present of TZD-OCH2CH3. LigPlot v.1.0, which generates from the PDB file input

Figure 5

Docking

The molecular docking would give the computational insight into the binding of TZD-OCH2CH3 to COX-2 and iNOS. The results of docking were well clustered around the conformer with the best score. According to Figure 4, the analysis of results showed that hydrophobic interactions play the major role in the binding of TZD-OCH2CH3 to COX-2 and iNOS hydrophobic pocket. Based on the results of the modeling, dominant interaction is hydrophobic. It is clear from Figure 5A, the active site of COX-2, that interacting with TZD-OCH2CH3 is composed from Asn43, Arg44, Phe64, Thr85, Asn87, Leu152, Glu465, Arg467, Lys468, Arg469, Ser 471, Lys473, and Glu520. Also, two hydrogen bonds were seen among TZD-OCH2CH3 and Tyr122 and Leu472 of Cox-2. Figure 5B was shown the Lig Plot diagram of the interaction between iNOS and TZD-OCH2CH3. Hydrophobic interaction plays the major role in the binding site.

The residues of binding site are consisted of Trp 188, Ala191, Pro 192, Arg193, Cys194, Leu203, Gln257, Arg260, Pro344, Val346, Met349, Phe 363, Tyr367, Glu 371, Asp376, and Arg382. Besides that, there was on hydrogen bond between Tyr483 of iNOS and TZD-OCH2CH3.

Discussion

Several anti-inflammatory agents such as 2,6-Dimethoxy-4-vinylphenol, cyclicpeptides, and teprenone with anticancer properties have been developed and patented by many pharmaceutical companies (37-39). Despite the fact that there have been many efforts to develop anti-inflammatory agents, there is still a large challenge for developing effective agents (40, 41).

Therefore, there is an urgent need to develop anti-inflammatory agents with novel mechanisms of action. In an attempt to identify novel anti-inflammatory agents, in present study we investigated the effects of TZD-OCH2CH3 on LPS-induced expression of iNOS and COX-2. During our search for novel anti-inflammatory agents from synthetic derivatives, we found that thiazolidine exhibited the anti-inflammatory properties; therefore, in this investigation our main objective is design, synthesis, and anti-inflammatory evaluation of a novel derivative of thiazolidineas inhibitors of expression of iNOS and COX-2. Importantly, iNOS and COX-2 has been shown to be responsible for the inflammatory activity and tumorigenesis (42). In RAW 264.7 cells, LPS induces the expression of iNOS, and thus, increases NO production (43). NO is a major macrophage-derived inflammatory mediator and the amount of production of NO may reflect the degree of inflammation (44).

To investigate the anti-inflammatory activity of TZD-OCH2CH3 was tested it effect on NO production in LPS-induced RAW 264.7 cells. TZD-OCH2CH3 inhibited nitrite production by approximately 45% at 60 μg/mL, also the results showed that TZD-OCH2CH3 was inhibitory effects on the production of NO in a concentration-dependent manner with an IC50 of 65 μg/mL. Liang Ma et al. (2015) introduced novel derivatives of thiazolidine ((Z)-N-(3-Chlorophenyl)-2-(4-((3-(methoxymethyl)-2,4- dioxothiazolidin-5-ylidene)methyl) phenoxy) acetamide and (Z)-N-(3-Chlorophenyl)-2-(4-((3-(3-dimethylamino)-2-methylpropyl)-2,4-dioxothiazolidin-5-ylidene) methyl) phenoxy) acetamide) that inhibit the production of the NO and the iNOS activity in LPS-induced RAW 264.7 macrophages with an IC50 values of 45.6 µM and 25.2 μM, respectively (45). Ma L et al. have reported that novel 5-benzylidenethiazolidine-2,4-dione derivatives inhibits iNOS expression in RAW 264.7 cells with an IC50 values of 8.66 µM (46). Also, previous studies indicated that the aspirin inhibited the production of the NO with an IC50 value of 3.0 mM (47). The COX-2 and iNOS mRNA expression was decreased by treatment of TZD-OCH2CH3 in the RAW264.7 macrophages compared to the stimulation by LPS alone. The treatment of LPS-activated RAW 264.7 cells with TZD-OCH2CH3 significantly inhibited LPS-induced COX-2 mRNA expression, corresponding to 37.10% and 67.76% at 30 and 60 μg/mL, respectively. These data suggest that the inhibition of nitric oxide production is not primarily due to a decreased level of iNOS mRNA, but decrease in the production of the NO might be resulted from the inhibition of the iNOS enzyme activity in treated RAW 264.7 cells by TZD-OCH2CH3. In conclusion, this study showed that TZD-OCH2CH3 significantly reduced the production of NO and COX-2 and iNOS mRNA expression in LPS-activated RAW 264.7 cells. Our findings suggested that the novel derivative of thiazolidine may be a potent synthetic anti-inflammatory agent.

Acknowledgements

References

  • 1.

    Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J. Physiol. Pharmacol. 2006;57:113.

  • 2.

    Park JY, Pillinger MH, Abramson SB. Prostaglandin E 2 synthesis and secretion: the role of PGE 2 synthases. Clin. Immunol. 2006;119:229-40. [PubMed ID: 16540375].

  • 3.

    Kean WF, Rainsford KD, Kean IRL. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology. 2008;16:53-75. [PubMed ID: 18389178].

  • 4.

    Luo Y, Ma L, Zheng H, Chen L, Li R, He C, Yang L, Wei Y. Discovery of (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. J. Med. Chem. 2009;53:273-81.

  • 5.

    Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sørensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450. [PubMed ID: 21727167].

  • 6.

    Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J.Clin. Oncol. 2005;23:2840-55. [PubMed ID: 15837998].

  • 7.

    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-70. [PubMed ID: 12490959].

  • 8.

    Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544-51. [PubMed ID: 11905709].

  • 9.

    Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60:2101-3. [PubMed ID: 10786667].

  • 10.

    Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002;62:2029-33. [PubMed ID: 11929821].

  • 11.

    Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA. 2008;52:1502-17.

  • 12.

    Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bástida G, Rodrigo L, Santolaria S, Güell M, de Argila CM, Quintero E, Borda F, Piqué JM. Asociación Española de Gastroenterología Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors traditional non-aspirin non-steroidal anti-inflammatory drugs aspirin and combinations. Gut. 2006;55:1731-8. [PubMed ID: 16687434].

  • 13.

    Beraldo H, Gambinob D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Rev. Med. Chem. 2004;4:31-9. [PubMed ID: 14754441].

  • 14.

    Dua R, Shrivastava S, Sonwane SK, Srivastava SK. Pharmacological significance of synthetic heterocycles scaffold: a review. Adv. Biol. Res. 2011;5:120-44.

  • 15.

    Bhatnagar A, Sharma PK, Kumar N. A review on imidazoles: Their chemistry and pharmacological potentials. Int. J. PharmTech Res. 2011;3:268-82.

  • 16.

    Jain VS, Vora DK, Ramaa CS. Thiazolidine-2, 4-diones: progress towards multifarious applications. Bioorg. Med. Chem. 2013;21:1599-620. [PubMed ID: 23419324].

  • 17.

    Luo Y, Ma L, Zheng H, Chen L, Li R, He C, Yang S, Ye X, Chen Z, Li Z, Gao Y, Han J, He G, Yang L, Wei Y. Discovery of (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. J.Med. Chem. 2009;53:273-81.

  • 18.

    Minkin VI, Garnovskii AD, Elguero J, Katritzky AR, Denisko OV. Tautomerism of heterocycles: five-membered rings with two or more heteroatoms. Adv. Heterocycl. Chem. 2000;76:157-323.

  • 19.

    Verma A, Saraf SK. 4-Thiazolidinone–A biologically active scaffold. Eur. J.Med. Chem. 2008;43:897-905. [PubMed ID: 17870209].

  • 20.

    Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A, Saraf SK. 4-Thiazolidinones: the advances continue. Eur. J.Med. Chem. 2014;72:52-77. [PubMed ID: 24355348].

  • 21.

    Sindhu J, Singh H, Khurana JM, Sharma C, Aneja KR. Multicomponent domino process for the synthesis of some novel 5-(arylidene)-3-((1-aryl-1H-1, 2, 3-triazol-4-yl) methyl)-thiazolidine-2, 4-diones using PEG-400 as an efficient reaction medium and their antimicrobial evaluation. Chin. Chem. Lett. 2015;26:50-4.

  • 22.

    Malik S, Upadhyaya PK, Miglani S. Thiazolidinediones: a plethro of biological load. Int. J. PharmTech Res. 2011;3:62-75.

  • 23.

    Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetes Res. 1999;16:179-92.

  • 24.

    Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549-58. [PubMed ID: 3053303].

  • 25.

    Zebardast T, Zarghi A, Daraie B, Hedayati M, Dadrass OG. Design and synthesis of 3-alkyl-2-aryl-1, 3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2009;19:3162-5. [PubMed ID: 19447036].

  • 26.

    Zarghi A, Javid FS, Ghodsi R, Dadrass OG, Daraei B, Hedayati M. Design, synthesis and biological evaluation of new 5, 5-diarylhydantoin derivatives as selective cyclooxygenase-2 inhibitors. Sci. Pharm. 2011;79:449.

  • 27.

    Schepetkin IA, Kirpotina LN, Khlebnikov AI, Hanks TS, Kochetkova I, Pascual DW, Jutila MA, Quinn MT. Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol. Pharmacol. 2012;81:832-45. [PubMed ID: 22434859].

  • 28.

    Vazzana I, Terranova E, Mattioli F, Sparatore F. Aromatic Schiff bases and 2, 3-disubstituted-1, 3-thiazolidin-4-one derivatives as antiinflammatory agents. Arkivoc. 2004;5:364-74.

  • 29.

    Mohammadi A, Safarnejad M. Synthesis, structural characterization and tautomeric properties of some novel bis-azo dyes derived from 5-arylidene-2, 4-thiazolidinone Spectrochim. Acta A Mol. Biomol. Spectrosc. 2014;126:105-11.

  • 30.

    Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48:4827-33. [PubMed ID: 3409223].

  • 31.

    Granger DL, Taintor RR, Boockvar KS. Determination of nitrate and nitrite in biological samples using bacterial nitrate reductase coupled with the Griess reaction. Methods. 1995;7:78-83.

  • 32.

    Word JM, Lovell SC, Richardson JS, Richardson DC. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 1999;285:1735-47. [PubMed ID: 9917408].

  • 33.

    Trott O, Olson AJ. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J.Comput. Chemistry. 2010;31:455-61.

  • 34.

    Sanner MF. Python: a programming language for software integration and development. J. Mol. Graph. Model. 1999;17:57-61. [PubMed ID: 10660911].

  • 35.

    Coleman WF, Arumainayagam CR. HyperChem 5 (by Hypercube, Inc). J. Chem. Educ. 1998;75:416.

  • 36.

    Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8:127-34. [PubMed ID: 7630882].

  • 37.

    Thiyam‐Holländer U, Aladedunye F, Logan A, Yang H, Diehl BWK. Identification and quantification of canolol and related sinapate precursors in Indian mustard oils and Canadian mustard products. Eur. J. Lipid. Sci. Tech. 2014;116:1664-74.

  • 38.

    Namjoshi S, Benson HAE. Cyclic peptides as potential therapeutic agents for skin disorders. Pept. Sci. 2010;94:673-80.

  • 39.

    Isomura Y, Yamaji Y, Yamada A, Watanabe Y, Suzuki H, Kobayashi Y, Yoshida S, Watabe H, Hirata Y, Yoshida H, Koike K. Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs. Gastrointest. Endosc. 2014;80:118-25. [PubMed ID: 24518124].

  • 40.

    Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140:935-50. [PubMed ID: 20303881].

  • 41.

    Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002;94:252-66. [PubMed ID: 11854387].

  • 42.

    Murakami A, Ohigashi H. Targeting NOX, INOS and COX2 in inflammatory cells: Chemoprevention using food phytochemicals. Int. J. Cancer. 2007;121:2357-63. [PubMed ID: 17893865].

  • 43.

    Chiou W, Chen C, Lin J. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 2647 cells by andrographolide. Br. J. Pharmacol. 2000;129:1553-60. [PubMed ID: 10780958].

  • 44.

    Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J. Leukoc. Biol. 1993;54:171-8. [PubMed ID: 7689630].

  • 45.

    Ma L, Pei H, Lei L, He L, Chen J, Liang X, Peng A, Ye H, Xiang M, Chen L. Structural exploration, synthesis and pharmacological evaluation of novel 5-benzylidenethiazolidine-2, 4-dione derivatives as iNOS inhibitors against inflammatory diseases. Eur. J. Med. Chem. 2015;92:178-90. [PubMed ID: 25555141].

  • 46.

    Ma L, Xie C, Ma Y, Liu J, Xiang M, Ye X, Zheng H, Chen Zh, Xu Q, Chen T, Chen J, Yang J, Qiu N, Wang G, Liang X, Peng A, Yang Sh, Wei Y, Chen L. Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2, 4-dione derivatives for the treatment of inflammatory diseases. J.Med. Chem. 2011;54:2060-8. [PubMed ID: 21381754].

  • 47.

    Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, Abramson SB. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 1995;92:7926-30. [PubMed ID: 7544010].